Provider Profile

Shahzad Raza, MD

Provider Profile

Shahzad Raza, MD

Oncology / Hematology
Call to make an appointment 816-932-3300

Education

Medical School
Dow Medical College , University of Karachi, Pakistan, Karachi,
Post-Grad Training
Internship, Dow Medical College , University of Karachi
Post-Grad Training
Dept. of Internal Medicine, Dow Medical College, University of Karachi, Karachi,
Educational Commission for Foreign Medical Graduates
Educational Commission for Foreign Medical Graduates, Philadelphia, PA
Residency
Internal Medicine, Brookdale University Hospital and Medical Center, Brooklyn, NY
Fellowship
Med/Hematology-Oncol, University of Missouri - Columbia Program, Columbia, MO

Board Certifications

  • American Board of Internal Medicine
  • American Board of Internal Medicine - Subspecialty in Hematology
  • American Board of Internal Medicine - Subspecialty in Medical Oncology

Clinical Interests

  • multiple myeloma and AL amyloidosis
  • neuropathies associated with plasma cell dyscrasia
  • lymphomas and leukemias
  • myeloproliferative neoplasms
  • bleeding and clotting disorders
  • central nervous system tumors

Biography

Dr. Raza is a board certified hematologist/oncologist and an expert in the field of malignant hematology. He joined Saint Luke’s Cancer Institute (SLCI) from New York Presbyterian Hospital/ Columbia University Medical Center, New York, an NCI designated comprehensive cancer center where he worked as Assistant Professor of Hematology & Oncology with a focus of treating complicated cases of  multiple myeloma, AL Amyloidosis and malignant lymphomas.

He has also served as principal investigator and co-investigator for clinical trials including chemotherapies and immunotherapies that have aimed at developing new treatments for multiple myeloma and AL Amyloidosis.

Previously, Dr. Raza conducted his research on “Cancer therapies and Angiogenesis” under the mentorship of Michael L. Gruber M.D. and Silvia Formenti M.D. His published work on anti-angiogenic therapies was widely recognized and presented in multiple peer reviewed conferences including American Society of Clinical Oncology, American Society of Hematology, Society of Neuro-Oncology and American Society for therapeutic radiology and oncology. His research has been cited in top medical journals including New Journal of Medicine, Lancet Oncology, British Journal of Hematology and many other journals. Dr. Raza is also an external reviewer for various top medical journals and serves as mentor for medical students, residents and fellows.

Due to his significant contribution to research and patient care, Dr. Raza was recognized as “Outstanding Fellow” by the State of Missouri. He was also awarded as “First Michael Perry Fellow Award” by the University of Missouri. In 2015, he was elected as “Fellow of American College of Physician (FACP)”, a distinction earned from colleagues recognize accomplishments and achievements over and above the practice of medicine.  

Dr. Raza believes in compassionate care for patients. His goal is to develop innovative clinical trials on immunotherapies, monoclonal antibodies, and novel small molecules in the management of multiple myeloma, lymphomas and leukemias. 

News

KSHB: Immunotherapy Helps Local Woman Beat Uncommon Form of Cancer
After being diagnosed with an extremely rare and deadly form of blood cancer, a Kansas City woman is now beating the odds with the help of immunotherapy.

Accepted Insurances

  • Aetna Choice POS II
  • Aetna Choice POS II Aexcel Local
  • Aetna Choice POS II Local
  • Aetna Elect Choice
  • Aetna Federal Employees Health Benefit Plan
  • Aetna HMO
  • Aetna HMO Local
  • Aetna Mail Handlers Benefit Plan
  • Aetna Managed Choice
  • Aetna MDOT & Missouri State Highway Patrol
  • Aetna Medicare
  • Aetna Missouri Preferred
  • Aetna MU myChoice Health Program
  • Aetna Open Choice PPO
  • Aetna Select
  • Aetna Select Local
  • Aetna Signature Administrators (ASA)
  • Aetna Workers Comp
  • BCBS of Kansas (call provider)
  • BCBS of Kansas City (PPO)
  • BCBS of Kansas City Freedom Network
  • BCBS of Kansas City Freedom Network Select
  • BCBS of Kansas City Preferred Care
  • BCBS of Kansas City Preferred Care Blue
  • BCBS of Kansas City Traditional
  • Blue Medicare Advantage Access (PPO)
  • Blue Medicare Advantage Complete (HMO)
  • Blue Medicare Advantage Essential (PPO)
  • Blue Medicare Advantage Plus (HMO)
  • Century Health Solutions (PPO)
  • Cigna (HMO)
  • Cigna (Open Access)
  • Cigna (PPO)
  • CompResults (WC)
  • Coventry Advantra Freedom (PPO)
  • Coventry Health and Life Insurance Company
  • Coventry Health Care
  • Coventry Medicare Advantra (PPO)
  • Golden Rule
  • Health Choice of Northwest Missouri (PPO)
  • Healthcare USA-MC+ (Aetna Better Health)
  • HealthLink (HMO)
  • HealthLink (PPO) through Freedom Network
  • Home State Health Plan (Missouri practices)
  • Humana (PPOx)
  • Humana Choice Care (PPO)
  • Humana Choice PPO (Medicare Advantage PPO)
  • Humana Community (HMO)
  • Humana Gold Choice Medicare Advantage PFFS
  • Humana Gold Plus (HMO)
  • Humana Gold Plus HMO SNP
  • Humana SmartExpress PPO
  • Humana SmartNet PPO
  • Humana SmartSuite PPO
  • HumanaOne
  • Integrated Health Plan
  • Kansas Medicaid
  • Medica Connect
  • Medica Select
  • Medicare
  • Missouri Care (Missouri practices only)
  • Missouri Medicaid
  • MultiPlan/PCHS (PPO)
  • Occupational Health Management (WC)
  • OHARA Managed Care (WC)
  • ProviDRs Care Network (formerly WPPA)
  • Pyramid Life (Medicare Advantage PPO)
  • Railroad Medicare
  • Sunflower State Health Plan (Kansas practices)
  • TRICARE
  • Triwest Veterans Affairs Patient Centered Community Care
  • United Healthcare Choice
  • United Healthcare Choice Plus
  • United Healthcare Community Plan
  • United Healthcare Definity Health Reimbursement Account
  • United Healthcare Definity Health Savings Account
  • United Healthcare Golden Rule HMO
  • United Healthcare Indemnity
  • United Healthcare Managed Indemnity
  • United Healthcare Options PPO
  • United Healthcare Select
  • United Healthcare Select Plus
  • UnitedHealthcare Evercare DH
  • UnitedHealthcare Evercare DH-POS
  • UnitedHealthcare Evercare DP
  • UnitedHealthcare Evercare RDP
  • UnitedHealthcare Medicare Choice
  • UnitedHealthcare Medicare Choice Essential
  • UnitedHealthcare Medicare Complete
  • UnitedHealthcare Medicare Complete Essential
  • UnitedHealthcare Medicare Complete Plus
  • UnitedHealthcare Medicare DH
  • UnitedHealthcare Medicare Plus Essential
  • US Department of Labor

Publications

Selected Publications

1.Rosenbaum E, Marks D, Raza S. Diagnosis and management of neuropathies associated with plasma cell dyscrasias. Hematol Oncol. 2017 Apr 10. PMID: 28397326

2.Raza S, Safyan S, Bowman A, Lentzsch S. Optimizing current and emerging therapies in multiple myeloma. A guide for the hematologist. Ther Adv Hematol. 2017;8(2):55-70. PMID: 28203342

3.Raza S, Rachel S, Lentzsch S. (2015) Immune Therapy in the management of multiple myeloma: Current Cancer Drug targets (chapter). Curr Cancer Drug Targets. 2017 Feb 13. PMID:28201976

4.Li S, Fu J, Lu C, Mapara MY, Raza S, Hengst U, Lentzsch S. Elevated Translation Initiation Factor eIF4E Is an Attractive Therapeutic Target in Multiple Myeloma. Mol Cancer Ther. 2016 Apr;15(4):711-9. PMID:26939700

5. Firwana B, Sonbol MB, Diab M, Raza S, Hasan R, Yousef I, Zarzour A, Garipalli A, Doll D, Murad MH, Al-Kali A. Tyrosine kinase inhibitors as a first-line treatment in patients with newly diagnosed chronic myeloid leukemia in chronic phase: A mixed-treatment comparison. Int J Cancer. 2015,11;138(6):1545-53.  PMID: 26455714

6.Raza S, Ali Baig M, Chang C, Dabas R, Akhtar M, Khan A, Nemani K, Alani R, Majumder O, Gazizova N, Biswas S, Patel P, Al-Hilli JA, Shad Y, Berger BJ, Zaman M. A prospective study on red blood cell transfusion related hyperkalemia in critically ill patients. J Clin Med Res. 2015 Jun; 7(6):417-21. PMID:25883703

7.Raza S, Kale G, Kim D, Akbar SA, Holm L, Naidzionak U, Hossain MA, Dong X, Doll DC, Freter CE, Hopkins T. Thromboprophylaxis and Incidence of Venous Thromboembolism in Patients With Hemophilia A or B Who Underwent High-Risk Orthopedic Surgeries. Clin Appl Thromb Hemost. 2014 Jul 9. pii: 1076029614543139. PMID:25008348

8.Raza S, Firwana B, Doll DC.  Bevacizumab alone or in combination with chemotherapy in glioblastomas? Comment on Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. [Lancet Oncol. 2014] Lancet Oncol. 2014 Oct;15(11):e472-3. PMID: 25281464

9.Raza S, Shortridge J, Kodali M, Nistala P, Kale G , Doll DC. Severe haemolytic anaemia with erythrophagocytosis following the bite of a brown recluse spider.  Br J Haematol. 2014 Oct;167(1):1.PMID:25040317

10.Raza S, Doll DC. Spontaneous splenic rupture in mantle cell lymphoma with leukemic variant. Blood. 2014 Jul 17; 124(3):316. PMID: 25162078

11.Tam M, Narayana A, Raza S, Kunnakkat S, Golfinos JG, Parker EC, Novik Y. Role of HER2 status in the treatment for brain metastases arising from breast cancer with sterotactic radiosurgery. Med Oncol. 2014; 31(2):832. PMID: 24390418

12.Barakat S, Odem J, Batanian JR, Raza S, Khan UZ. Papillary thyroid cancer in struma testis with malignant transformation in the lung associated with trisomy 17 successfully treated with total thyroidectomy and radioiodine ablation. Case Rep Oncol. 2014 Nov 12;7(3):751-7. PMID: 25520651

13.Raza S, Chaudhry NA, Brown JD, Aghaie S, Rezai D, Khan A, Tan Pde L, Berger BJ. To Study the Clinical, Biochemical and Radiological Features of Acute Pancreatitis in HIV and AIDS. J Clin Med Res. 2013; 5(1):12-7. PMID:23390470

14.Raza S, Kirkland RS, Patel AA, Shortridge JR, Freter C. Insight into Sweet's syndrome and associated-malignancy: A review of the current literature. Int J Oncol. 2013;42(5):1516-22. PMID:23546524 

15.Regunath H, Shortridge J, Raza S, Nistala P, Huffman B, Wang M, Xiang D.  Occult pulmonary mucosa‑associated lymphoid tissue lymphoma presenting as catastrophic antiphospholipid antibody syndrome. Oncology Letters, 2013, 6:1261-1264. PMID: 24179505

16.Akbar S.A, Raza S, Denney J.E. Johannesen E.J, Doll D.C. Systemic Mastocytosis Presenting as Acute Appendicitis: A Case Report and Review of the Literature. Case Rep Oncol 2013;6: 174-179. PMID:23626557. 

17.Guy JP, Raza S, Bondi E, Rosen Y, Kim DS, Berger BJ. Cryptococcus pneumonia presenting in an immunocompetent host with pulmonary asbestosis: a case report. J Med Case Rep. 2012; 6(1):170. PMID:22742509

18.Ibrahim R, Khan A, Raza S, Kafeel M, Dabas R, Haynes E, Gandhi A, Majumder OL, Zaman M. Triad of iron deficiency anemia, severe thrombocytopenia and menorrhagia-a case report and literature review. Clin Med Insights Case Rep. 2012;5: 23-7. PMID:22493563

19.Khan A, Khan Y, Raza S, Akbar G, Khan M, Diwan N, Rizvi W. Functional parathyroid cyst: a rare cause of malignant hypercalcemia with primary hyperparathyroidism-a case report and review of the literature. Case Report Med. 2012;2012:851941. PMID:22431942

20.Hardee ME, Raza S, Becker SJ, Jozsef G, Lymberis SC, Hochman T, Goldberg JD, DeWyngaert KJ, Formenti SC. Prone hypofractionated whole-breast radiotherapy without a boost to the tumor bed: comparable toxicity of IMRT versus a 3D conformal technique. Int J Radiat Oncol Biol Phys. 2012; 82 (3):e415-23. PMID:22019349

21.Raza S, Lymberis SC, Ciervide R, Axelrod D, Fenton-Kerimian M, Magnolfi C, Rosenstein B, Dewyngaert JK, Formenti SC. Comparison of Acute and Late toxicity of two regimens of 3- and 5-Week Concomitant Boost IMRT to Standard 6-Week Breast Radiotherapy. Front Oncol. 2012; 2:44. PMID:22649788

22.Narayana A, Gruber D, Raza S, Patrical E, Beyerl D, Zampella E, Parker E, Golfinos J, Gruber M. A Clinical Trial of Bevacizumab, Temozolomide, and Radiation for Newly-Diagnosed Glioblastoma Multiforme, J Neurosurg. 2012; 116(2): 341-5. PMID: 22035272

23.Poddar N, Raza S, Sharma B, Liu M, Gohari A, Kalavar M. Small bowel adenocarcinoma presenting with refractory iron deficiency anemia - case report and review of literature. Case Rep Oncol. 2011; 4(3):458-63. PMID:22087098

24.Khan A, Raza S, Batul SA, Khan M, Aksoy T, Baig M, Berger BJ. The Evolution of Clostridium difficile Infection in Cancer Patients: Epidemiology, Pathophysiology, and Guidelines for Prevention and Management. Recent Pat Antiinfect Drug Discov 2012; 7(2): 157-170. PMID: 22792862 

25.Narayana A, Kunnakkat S, Chacko-Mathew J, Gardner S, Karajannis M, Raza S, Wisoff J, Weiner H, Harter D, Allen J. Bevacizumab in recurrent high-grade pediatric gliomas. Neuro Oncol.12(9): 985-990, 2010. PMID: 20363768

26.Raza S, Kornblum N, Kancharla VP, Baig MA, Singh AB, Kalavar M. Emerging therapies in the treatment of locally advanced squamous cell cancers of head and neck Recent Pat Anticancer Drug Discov. 2011;6(2):246-57. PMID:21247406 

27.Raza S, Naik S, Kancharla VP, Tafera F, Kalavar MR. Dual-Positive (CD4+/CD8+) Acute Adult T-Cell Leukemia/Lymphoma Associated with Complex Karyotype and Refractory Hypercalcemia: Case Report and Literature Review. Case Rep Oncol. 2010;3(3):489-94. PMID:21611103

28.Raza S, Baig MA, Russell H, Gourdet Y, Berger BJ. Clostridium Difficile Infection Following Chemotherapy. Recent Pat Antiinfect Drug Discov. 2010 Jan;5(1):1-9. PMID: 19929843 

29.Raza S, Mahmood K, Hakeem A, Polsky S, Haemel A, Rai S, Baig MA. Adverse clinical sequelae after skin branding: a case series. J Med Case Reports. 2009 Jan 23;3(1):25 PMID:19166615

30.Raza S, Donach M. Bevacizumab in Adult Malignant Brainstem Gliomas. Neurooncol. 2009; 95(2):299-300, PMID: 19506812

31.Raza S, Baig M, Ali J, Rizvi S. To study hypoactive sexual desire disorder in a fragile X carrier female successfully treated with local testosterone application.  Int J Impot Res (Nature publication group), 2008; 20(2):226-8. PMID: PMID:17851581

32.Hakeem A, Dhakam S, Tai J, Bakhtawar H, Nazim MH, Raza S, Bhatti S. Early and long term outcome of rescue percutaneous coronary intervention (R-PCI): experience from a tertiary care center in Pakistan. Outcome of rescue angioplasty in Pakistan. J Thromb Thrombolysis. 2008; 27(3):287-292.  PMID: 18301868

33.Narayana A, Kelly P, Golfinos J, Parker E, Johnson G, Knopp E, Zagzag D, Fischer I, Raza S, Medabalmi P, Eagan P, Gruber M. Anti-angiogenic therapy using Bevacizumab in recurrent high grade glioma: Impact on local control and survival.  J Neurosurg 2008; Jan; 110(1):173-80. PMID:18834263

34.Fischer I, Cunliffe CH, Bollo RJ, Raza S, Monoky D, Chiriboga L, Parker EC, Golfinos JG, Kelly PJ, Knopp EA, Gruber ML, Zagzag D, Narayana A. High-grade glioma before and after treatment with radiation and Avastin: initial observations. Neuro Oncol. 2008 Oct; 10(5): 700-8. PMID: 18697955

35. Narayana A, Golfinos J, Fischer I, Raza S, Kelly P, Parker E, Knopp E, Medabalmi P, Zagzag D, Eagan P, Gruber M. Feasibility of using Bevacizumab with radiation therapy in newly diagnosed high grade gliomas. Int J Radiat Oncol Biol Phys. 2008 Oct 1; 72(2):383-9 PMID: 18793954

36. Hakeem A, Raza S, Moinuddin S, Bhatti S, Khalid I, Noor R, Mahmood K. Cirrhosis in Werner's syndrome: An unusual presentation of premature aging. Medical Science Monitor. 2007; 13(5):CS61-66.PMID: 17476199

 

Presentations at National Meetings

1. Edwards C,  Gould J, Langer A, Mapara M, Radhakrishnan J, Maurer M, Raza S, Mears J, Wall J, Solomon A, Lentzsch S.Analysis of the Phase 1a/b study of chimeric Fibril-Reactive monoclonal antibody 11-1F4 in patients with AL Amyloidosis.  Oral Presentation at 58th American Society of Hematology, Blood 2016 128:4523

2. Galina GL, Lentzsch S, Comenzo R, Zonder J, Osman K, Gould J, Tsai Wei-Yann, Pregja S, Raza S, Sanchorawala V, Landau J Final Results of a Phase 2 Study of Bendamustine in Combination with Dexamethasone in Patients with Previously Treated Systemic Light-Chain (AL) Amyloidosis . Presented  at 58th American Society of Hematology, Blood 2016 128:4523

3. Langer A, Miao S, Mapara M, Radhakrishnan J, Maurer M, Raza S, Mears J, Solomon A, Lentzsch S. Results of Phase I Study of Chimeric Fibril-Reactive Monoclonal Antibody 11-1F4 in Patients with AL Amyloidosis. Oral Presentation at 57th American Society of Hematology, 2015. Blood 2015 126:188. 

4. Lentzsch S, Comenzo R, Zonder J, Osman K, Susanna M, Backenroth D,  Otap D, Tsai Wei-Yann, Pregja S, Raza S, Sanchorawala V, Landau J.  Updated Results of a Phase 2 Study of Bendamustine in Combination with Dexamethasone (Ben/Dex) in Patients with Previously-Treated Systemic Light-Chain (AL) Amyloidosis.  Presented at 57th American Society of Hematology, 2015. Blood 2015 126:188. 

5. Firwana B, Sonbol M, Diab M, Hasan R, Yousef I, Garipalli A, Raza S, Al-Kali A, Doll D. Long Term Outcomes of First Line Tyrosine Kinase Inhibitors for Chronic Phase Chronic Myeloid Leukemia: A Mixed-Treatment Comparison. Presented at 2014 Annual American Society of Hematology (ASH) meeting, San Francisco, California, USA. Blood, 124 (21), 2014

6. Raza S, Kale G, Lata A, Hossain. Survival disparities and trend of head and neck cancer in the United States: A surveillance, epidemiology, and end results (SEERs) database study (1973-2010). Presented at 2014 ASCO Annual Meeting. J Clin Oncol 32:5s, 2014 (suppl; abstr 6066)

7. Firwana B, Diab M, Sonbol BM, Hasan R, Raza S, Doll D. Tyrosine kinase inhibitors as a first-line treatment in patients with newly diagnosed chronic myeloid leukemia in chronic phase: A mixed-treatment comparison. Presented at 2014 ASCO Annual Meeting. J Clin Oncol 32:5s, 2014 (suppl; abstr 7054)  

8. Manandhar N, Raza S. Doll D.  Tension Pneumocephalus undiagnosed entity in nasopharyngeal carcinoma. Presented at 2014 Annual American College of Physician Meeting , September 2014, Lake of Ozark, Missouri, USA

9. Wang Y, Raza S,  Johannesan EJ, Huffman B, Freter C, Wang M. Metachronous Anaplastic Large Cell Lymphoma And Plasma Cell Neoplasms In The Same Patient, Coincident Or Correlated?" Poster presented at: The College of American Pathologists 2013 Annual Meeting. Archives of Pathology & Laboratory Medicine: 2013; 137, 10. Abstract No: 74

10.Raza S, Hossain MAkm, Rahman R, Freter C, Abraham J. Epidemiologic and survival characteristics of breast cancer (BC) among the U.S. Asian Indian and Pakistani women compared with other U.S. population groups: A SEER database study. Presented at : 2013 Annual Breast Cancer symposium, American Society of Clinical Oncology. J Clin Oncol, 2013;  31: s26. Abstract 19

11.Raza S,  Kim D,  Holm  L, Naidzionak U,  Dong  X, , Hossain M,  Hopkins  T. Thromboprophylaxis and incidence of Venous Thromboembolism (VTE) in patients with hemophilia A or B who underwent for elective Total Hip Replacement or Total Knee Arthroplasty. A Tertiary care University Hospital experience. Presented at: 23rd Annual Mayo Clinic Hematology/Oncology Reviews (August, 2013), Amelia Island, Florida, USA.

12.Baig M, Raza S. Anemia a commonly missed diagnosis by physicians. Poster presented at:  Annual Bronx county medical society, 2010

13.Raza S, Narayana A, Morsi A, Parker E, Rush S, Novik Y. Outcomes of stereotactic radiosurgery in the management of brain metastasis in patients with HER2 positive metastatic breast cancer.  Poster presented at 32nd San Antonio Breast Conference, Cancer Research: 2009; 69 (24): S3. 

14.Gruber M, Raza S, Gruber D,  Narayana A. Bevacizumab in combination with radiotherapy plus concomitant and adjuvant temozolomide for newly diagnosed glioblastoma: Update progression-free survival, overall survival, and toxicity Poster presented at: 45th Annual American Society of Clinical Oncology meeting, J Clin Oncol 2009; 27:15s Abstract no 2017

15.Raza S, Lymberis S, DeWyngaert K , Fenton-Kerimian M, Donach M,  Formenti S. Six-week Standard Fractionation Breast Radiotherapy Versus Five-week With A Concomitant Boost: Acute And Late Toxicity. Poster presented at: 51st  Annual American Society for therapeutic radiology and oncology, Int J Radiat Oncol Biol Phys 2009;75(3): S219-S219

16.Fishcer I, Raza S, ZagZag D, Gruber LM, Narayana A. Predicting Response of VEGFR2 after bevacizumab therapy. Poster presented at: Society of Neuro-Oncology; Las Vegas, NV. Neuro-Oncol,2008;  10(5):855-856

17. P. N. Shah, V. A. Kumar, E. Jung, E. Knopp, J. Babb, G. Johnson, M. Gruber, D. Zagzag, S. Raza, A. Narayana. Comparison of Dynamic Susceptibility Contrast MRI with conventional MRI in evaluating tumor response following Bevacizumab therapy in recurrent high-grade gliomas: Poster presented at: 44th Annual meeting, American Society of Clinical Oncology, J Clin Oncol 2008; 26(15): 110s. Abstract 2085

18.A Narayana, S Raza , J Golfinos ,  G  Johnson,   A Knopp, D Zagzag , I Fischer, M Gruber. Anti-angiogenic therapy in recurrent high grade glioma: Impact on local control and survival. Poster presented at: 44th Annual meeting, American Society of Clinical Oncology, J Clin Oncol 2008; 26(15): 621s. Abstract# 13000  

19. Narayana A, Golfinos G. J, Raza S, Knopp E, Medabalmi P, Parker E, Zagzag D, Gruber LM. Change in Pattern of Relapse Following Anti-angiogenic Therapy in High Grade Glioma., Oral Presentation at: 51st  Annual American Society for therapeutic radiology and oncology Int J Radiat Oncol Biol Phys, 2008; 72(1): S11-S11

On Staff At

  • Saint Luke's East Hospital
  • Saint Luke's Hospital of Kansas City
  • Saint Luke's North Hospital–Barry Road
  • Saint Luke's North Hospital–Smithville
  • Saint Luke's South Hospital